The DOI matches its Crossref record; 68 of the 68 references it cites were found in a registry or an index.
Insulin Resistance and Cardiovascular Disease1
Abstract
INSULIN RESISTANCE describes an impaired biological response to insulin (1–4). In the early states of insulin resistance there is a compensatory increase in insulin concentrations. Although hyperinsulinemia may compensate for resistance to some biological actions of insulin, it may result in overexpression of actions in tissues that retain normal or minimally impaired sensitivity to insulin. Also, high concentrations of insulin can act through receptors for insulin-like growth factor I (IGF-I) (5–8). Thus, accentuation of some actions of insulin with concurrent resistance to other actions gives rise to diverse clinical manifestations and sequelae of the insulin resistance syndrome. In general, insulin resistance can be due to a prereceptor, receptor, or postreceptor abnormality (1). One signaling pathway for insulin and IGF-I is the phosphatidylinositide 3-kinase (PI3 -kinase) system. Upon binding to their receptors, there is autophosphorylation of the β-subunit, which mediates noncovalent but stable interactions between the receptor and cellular proteins (1). Several proteins are then rapidly phosphorylated on tyrosine residues by ligand-bound insulin receptors, including insulin receptor substrate-1 (IRS-1) (1). IRS docking proteins bind strongly to the enzyme PI3 -kinase (1), a heterodimer consisting of a p85 regulatory subunit and a p110 catalytic subunit, via SH-2 domain interaction with the p85 subunit (1). Insulin and IGF-I stimulation increases the amount of PI3 -kinase associated with IRS, and the binding process is associated with increased activity of the enzyme. Activation of the enzyme is crucial for transducing the actions of these peptides in cardiovascular (CV) tissue (9–14) as well as conventional insulin-sensitive tissues (1). The interruption of this pathway creates a resistance to the actions of insulin/IGF-I in stimulating vascular nitric oxide (NO) production (9, 10), CV cation transport mechanisms (11, 12–15), as well as glucose transport (1, 6) (Fig. 1) in classically sensitive tissues such as muscle and adipose tissue. PI3-kinase mediates the increases in NO, Na+ pump, K+ channel, and calcium (Ca2+) myofilament sensitivity by increasing the trafficking and translocation of NO synthase and cation pump units as well as glucose transporters (1, 9, 16) (Fig. 2). Therefore, resistance to the actions of insulin and IGF-I in these tissues occurs whenever there is reduced PI3 -kinase activation (Fig. 2). The actions of insulin and IGF-I on cation metabolism and vascular tone. The actions of insulin and IGF-I on cation metabolism and vascular tone. The interactions of insulin/IGF-I and the RAS in cardiovascular tissue (−) indicates insulin/IGF-I signaling steps that are inhibited by Ang II. The interactions of insulin/IGF-I and the RAS in cardiovascular tissue (−) indicates insulin/IGF-I signaling steps that are inhibited by Ang II. Evidence has been garnered indicating that insulin resistance and the resultant hyperinsulinemia are causally related to hypertension (Table 2). First, untreated essential hypertensive patients have higher fasting and postprandial insulin levels than normotensive subjects regardless of body mass; a direct correlation between plasma insulin concentrations and blood pressure levels exists (17, 18). Second insulin resistance and hyperinsulinemia exist in rats with genetic hypertension such as the Dahl hypertensive (19), the spontaneously hypertensive (20), and the Zucker obese hypertensive rat strain (21). Finally, the relationship between insulin and hypertension seen in essential hypertension does not occur with secondary hypertension (20, 22). Accordingly, insulin resistance and hyperinsulinemia are not consequences of hypertension, but, instead, a genetic predistribution may contribute to both disorders. This concept is supported by the finding of altered glucose metabolism in normotensive offspring of hypertensive persons (22–24). Mechanisms for the development of hypertension in insulin resistance/hyperinsulinemia include activation of the sympathetic nervous system, renal sodium retention, altered transmembrane cation transport, growth-promoting effects of vascular smooth muscle cells, and vascular hyperreactivity (1–3). Cardiovascular risk factors that cluster with microalbuminuria Cardiovascular risk factors that cluster with microalbuminuria Four large prospective studies (25–28) have shown that hyperinsulinemia is a predictor of coronary artery disease (CAD), with a few prospective reports not demonstrating such a relationship. The greatest association of hyperinsulinemia with CAD has been found in Finland in a population with a very high frequency of CAD (25). Results of a prospective investigation of 2103 men from Quebec (29) clearly showed that high fasting insulin concentrations are an independent predictor of CAD. This important study used an insulin assay without cross-reactivity with proinsulin, thus avoiding that confounding influence. Several rec
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
(2000) · New England Journal of Medicine · doi:10.1056/nejm200001203420301 · Cited by 8,663
Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men
Ridker, P. M., Cushman, M., Stampfer, M. J., Tracy, R. P., & Hennekens, C. H. (1997) · New England Journal of Medicine · doi:10.1056/nejm199704033361401 · Cited by 5,504
Insulin Resistance in Essential Hypertension
Ferrannini, E., Buzzigoli, G., Bonadonna, R., Giorico, M. A., Oleggini, M., Graziadei, L., Pedrinelli, R., Brandi, L., & Bevilacqua, S. (1987) · New England Journal of Medicine · doi:10.1056/nejm198708063170605 · Cited by 2,344
Hansson, L., Lindholm, L. H., Niskanen, L., Lanke, J., Hedner, T., Niklason, A., Luomanmäki, K., Dahlöf, B., de Faire, U., Mörlin, C., et al. (1999) · The Lancet · doi:10.1016/s0140-6736(98)05012-0 · Cited by 2,014
Thompson, S. G., Kienast, J., Pyke, S. D. M., Haverkate, F., & van de Loo, J. C. W. (1995) · New England Journal of Medicine · doi:10.1056/nejm199503093321003 · Cited by 1,821
Hyperinsulinemia as an independent risk factor for ischemic heart disease
Després, J.-P., Lamarche, B., Mauriège, P., Cantin, B., Dagenais, G. R., Moorjani, S., & Lupien, P.-J. (1996) · New England Journal of Medicine · doi:10.1056/nejm199604113341504 · Cited by 1,699
Steinberg, H. O., Chaker, H., Leaming, R., Johnson, A., Brechtel, G., & Baron, A. D. (1996) · Journal of Clinical Investigation · doi:10.1172/jci118709 · Cited by 1,687 · cited 2×
“Second, insulin stimulation of blood flow is blunted in these individuals (59, 60, 62).”
BackgroundReaven, G. M., Lithell, H., & Landsberg, L. (1996) · New England Journal of Medicine · doi:10.1056/nejm199602083340607 · Cited by 1,435
Hypertension and Antihypertensive Therapy as Risk Factors for Type 2 Diabetes Mellitus
Gress, T. W., Nieto, F. J., Shahar, E., Wofford, M. R., & Brancati, F. L. (2000) · New England Journal of Medicine · doi:10.1056/nejm200003303421301 · Cited by 1,202
Le Roith, D. (1997) · New England Journal of Medicine · doi:10.1056/nejm199702273360907 · Cited by 897
Research works printed but not linked: 1
- 1999, Hypertension in type II diabetes: update on therapy., J Clin Hypertens, 1, 41
Cited by
Subcutaneous and visceral adipose tissue: Structural and functional differences
Ibrahim, M. M. (2010) · Obesity Reviews · doi:10.1111/j.1467-789x.2009.00623.x · Cited by 2,238
Calhoun, D. A., Jones, D., Textor, S., Goff, D. C., Murphy, T. P., Toto, R. D., White, A., Cushman, W. C., White, W., Sica, D., et al. (2008) · Circulation · doi:10.1161/circulationaha.108.189141 · Cited by 2,237
Insulin and insulin resistance:
Sowers, J. R., & Frohlich, E. D. (2004) · Medical Clinics of North America · doi:10.1016/s0025-7125(03)00128-7 · Cited by 1,518
Self-citationCalhoun, D. A., Jones, D., Textor, S., Goff, D. C., Murphy, T. P., Toto, R. D., White, A., Cushman, W. C., White, W., Sica, D., et al. (2008) · Hypertension · doi:10.1161/hypertensionaha.108.189141 · Cited by 1,413
Kirpichnikov, D., McFarlane, S. I., & Sowers, J. R. (2002) · Annals of Internal Medicine · doi:10.7326/0003-4819-137-1-200207020-00009 · Cited by 1,084
Self-citationInsulin resistance, cardiovascular stiffening and cardiovascular disease
Hill, M. A., Yang, Y., Zhang, L., Sun, Z., Jia, G., Parrish, A. R., & Sowers, J. R. (2021) · Metabolism · doi:10.1016/j.metabol.2021.154766 · Cited by 1,045
Self-citationObesity as a cardiovascular risk factor
Sowers, J. R. (2003) · The American Journal of Medicine · doi:10.1016/j.amjmed.2003.08.012 · Cited by 584
Self-citationInsulin resistance and hypertension
Sowers, J. R. (2004) · American Journal of Physiology-Heart and Circulatory Physiology · doi:10.1152/ajpheart.00026.2004 · Cited by 471
Self-citationPolycystic ovarian syndrome (PCOS): Long-term metabolic consequences
Anagnostis, P., Tarlatzis, B. C., & Kauffman, R. P. (2018) · Metabolism · doi:10.1016/j.metabol.2017.09.016 · Cited by 416
Mortality in Patients with Pituitary Disease
Sherlock, M., Ayuk, J., Tomlinson, J. W., Toogood, A. A., Aragon-Alonso, A., Sheppard, M. C., Bates, A. S., & Stewart, P. M. (2010) · Endocrine Reviews · doi:10.1210/er.2009-0033 · Cited by 392
Rader, D. J. (2007) · The American Journal of Medicine · doi:10.1016/j.amjmed.2007.01.003 · Cited by 346
Molecular Signatures of Obstructive Sleep Apnea in Adults: A Review and Perspective
Arnardottir, E. S., Mackiewicz, M., Gislason, T., Teff, K. L., & Pack, A. I. (2009) · Sleep · doi:10.1093/sleep/32.4.447 · Cited by 345
Carroll, S., & Dudfield, M. (2004) · Sports Medicine · doi:10.2165/00007256-200434060-00004 · Cited by 327
Adrenal incidentaloma: a new cause of the metabolic syndrome?
Terzolo, M., Pia, A., Alì, A., Osella, G., Reimondo, G., Bovio, S., Daffara, F., Procopio, M., Paccotti, P., Borretta, G., et al. (2002) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.87.3.8277 · Cited by 322
Renin-angiotensin-aldosterone system and oxidative stress in cardiovascular insulin resistance
Cooper, S. A., Whaley-Connell, A., Habibi, J., Wei, Y., Lastra, G., Manrique, C., Stas, S., & Sowers, J. R. (2007) · American Journal of Physiology-Heart and Circulatory Physiology · doi:10.1152/ajpheart.00522.2007 · Cited by 317
Self-citationPleiotropic Effects of Statins: Lipid Reduction and Beyond
McFarlane, S. I. (2002) · Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.87.4.1451 · Cited by 314
Self-citationAngiotensin II-induced NADPH Oxidase Activation Impairs Insulin Signaling in Skeletal Muscle Cells
Wei, Y., Sowers, J. R., Nistala, R., Gong, H., Uptergrove, G. M.-E., Clark, S. E., Morris, E. M., Szary, N., Manrique, C., & Stump, C. S. (2006) · Journal of Biological Chemistry · doi:10.1074/jbc.m601320200 · Cited by 297
Self-citationPrevention of Type 2 Diabetes Mellitus Through Inhibition of the Renin-Angiotensin System
Scheen, A. J. (2004) · Drugs · doi:10.2165/00003495-200464220-00004 · Cited by 293
Orio, F., Palomba, S., Spinelli, L., Cascella, T., Tauchmanovà, L., Zullo, F., Lombardi, G., & Colao, A. (2004) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2003-032049 · Cited by 275
Insulin Resistance, Hyperinsulinemia, and Renal Injury: Mechanisms and Implications
Sarafidis, P. A., & Ruilope, L. M. (2006) · American Journal of Nephrology · doi:10.1159/000093632 · Cited by 272
Subclinical Cushing’s syndrome in adrenal incidentalomas
Terzolo, M., Bovio, S., Reimondo, G., Pia, A., Osella, G., Borretta, G., & Angeli, A. (2005) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/j.ecl.2005.01.008 · Cited by 179
Obesity, Peroxisome Proliferator-Activated Receptor, and Atherosclerosis in Type 2 Diabetes
Blaschke, F., Takata, Y., Caglayan, E., Law, R. E., & Hsueh, W. A. (2006) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/01.atv.0000191663.12164.77 · Cited by 176
Diabetes, hypertension, and cardiovascular derangements: Pathophysiology and management
El-Atat, F., McFarlane, S. I., & Sowers, J. R. (2004) · Current Hypertension Reports · doi:10.1007/s11906-004-0072-y · Cited by 121
Self-citationHepatitis C virus infection and insulin resistance
Bose, S. K. (2014) · World J Diabetes · doi:10.4239/wjd.v5.i1.52 · Cited by 118
Hypertension in Cushing’s Syndrome: From Pathogenesis to Treatment
Cicala, M. V., & Mantero, F. (2010) · Neuroendocrinology · doi:10.1159/000314315 · Cited by 112
The case for low carbohydrate diets in diabetes management
Arora, S. K., & McFarlane, S. I. (2005) · Nutrition & Metabolism · doi:10.1186/1743-7075-2-16 · Cited by 102
Self-citationIbáñez, L., Ong, K., Ferrer, A., Amin, R., Dunger, D., & de Zegher, F. (2003) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2002-022002 · Cited by 100
Bozorgmanesh, M., Hadaegh, F., & Azizi, F. (2010) · Lipids in Health and Disease · doi:10.1186/1476-511x-9-100 · Cited by 81
Subclinical Cushing's syndrome.
Terzolo, M., Reimondo, G., Bovio, S., & Angeli, A. (2004) · Pituitary · doi:10.1007/s11102-005-4024-6 · Cited by 80
Simonson, G. D., & Kendall, D. M. (2005) · Coronary Artery Disease · doi:10.1097/00019501-200512000-00002 · Cited by 38
McFarlane, S. I., Shin, J. J., Rundek, T., & Bigger, J. T. (2003) · Current Diabetes Reports · doi:10.1007/s11892-003-0070-5 · Cited by 28
Self-citationBerra, C. C., Rossi, M. C., Mirani, M., Ceccarelli Ceccarelli, D., Romano, C., Sassi, L., Peretti, E., Favacchio, G., Pastore, I., Folini, L., et al. (2023) · Frontiers in Endocrinology · doi:10.3389/fendo.2022.1099451 · Cited by 28
Metadata
- Authors
- McFarlane, S. I., Banerji, M., & Sowers, J. R.
- Venue
- The Journal of Clinical Endocrinology & Metabolism
- Publisher
- The Endocrine Society
- Published
- 2001-02-01
- Volume
- 86
- Issue
- 2
- Pages
- 713-718
- ISSN
- 0021-972X (ISSN-L)
- 1945-7197
- OpenAlex
- W2051181865
- Cited by
- 501
- References
- 68
- FWCI
- 19.70
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.